Related references
Note: Only part of the references are listed.A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR
James M. Cleary et al.
INVESTIGATIONAL NEW DRUGS (2020)
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate
Mark G. Anderson et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Safety and efficacy of depatuxizumab mafodotin plus temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
Andrew B. Lassman et al.
NEURO-ONCOLOGY (2019)
Efficacy and Safety Results of Depatuxizumab Mafodotin (ABT-414) in Patients With Advanced Solid Tumors Likely to Overexpress Epidermal Growth Factor Receptor
Glenwood D. Goss et al.
CANCER (2018)
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Andrew C. Phillips et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a
Ingrid Julienne Georgette Burvenich et al.
THERANOSTICS (2018)
Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft
Vanessa Izquierdo-Sanchez et al.
MOLECULES (2018)
Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma
Licun Wu et al.
CLINICAL CANCER RESEARCH (2017)
Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
H. L. Kindler et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
Martin van den Bent et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.
Emiliano Calvo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a
Ingrid J. G. Burvenich et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies
Sandra Salvi et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Andrew C. Phillips et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR).
George R. Blumenschein et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A phase 1 study of ABT-806 in subjects with advanced solid tumors
James M. Cleary et al.
INVESTIGATIONAL NEW DRUGS (2015)
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody
Edward B. Reilly et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Examining the utility of patient-derived xenograft mouse models
Samuel Aparicio et al.
NATURE REVIEWS CANCER (2015)
Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2014)
A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology
Scott C. Jeffrey et al.
BIOCONJUGATE CHEMISTRY (2013)
Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy
Hui K. Gan et al.
CANCER RESEARCH (2012)
Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma
Jun Kurai et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?
Vijay Agarwal et al.
CANCER TREATMENT REVIEWS (2011)
Epidermal Growth Factor Receptor Overexpression in Malignant Pleural Mesothelioma: Prognostic Correlations
Ottavio Rena et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation
Nola J. Olsen et al.
MEDICAL JOURNAL OF AUSTRALIA (2011)
HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts
Tapan K. Nayak et al.
PLOS ONE (2011)
89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
Jason P. Holland et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Eli C. F. Dijkers et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
David M. Jackman et al.
CANCER (2008)
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma
Kaitlyn J. Kelly et al.
HUMAN GENE THERAPY (2008)
Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma
K. Okuda et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group study
Linda L. Garland et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
Andrew M. Scott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis
Daniele Martarelli et al.
BMC CANCER (2006)
EGFR overexpression in malignant pleural mesothelioma - An immunohistochemical and molecular study with clinico-pathological correlations
A Destro et al.
LUNG CANCER (2006)
Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
C Panousis et al.
BRITISH JOURNAL OF CANCER (2005)
Gefitinib in patients with malignant mesothelioma: A phase II study by the cancer and leukemia group B
R Govindan et al.
CLINICAL CANCER RESEARCH (2005)
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor
TG Johns et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
